Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07047820 · ClinicalTrials.gov registry record
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
A clinical trial of Depression, Postpartum, sponsored by Biogen.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT07047820: Recruiting study of Depression, Postpartum, sponsored by Biogen.
NCT07047820 is a study of Depression, Postpartum that is actively recruiting participants, run by Biogen. The registered enrollment target is 200 participants, above the 150-participant average among 15 other Depression, Postpartum trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07047820, a study of Depression, Postpartum, is actively recruiting participants, sponsored by Biogen.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD. After giving birth, adults with PPD can suffer from symptoms such as tiredness, sadness, and a loss of interest in their daily activities. This study is known as an observational study, which means it collects health information about study participants after a healthcare professional has already prescribed treatment. Participants for this study will be found in the United States using a database from CVS Specialty Pharmacy. This will include anyone who was prescribed zuranolone between June 2025 and May 2026 and who filled the prescription within 1 year after the end of their pregnancy. The main goal of this study is to learn more about how zuranolone affects the participants' PPD symptoms. This will be measured using a questionnaire completed by participants called the Edinburgh Postnatal Depression Scale, also known as the EPDS. A higher score on the EPDS may indicate more severe PPD symptoms. The main question researchers want to answer in this study is: \- Do PPD symptoms change after treatment with zuranolone based on EPDS scores measured at Day 15? Researchers will also learn more about: * Changes in participants' EPDS scores from before treatment to Day 45, which is 30 days after treatment ends. * How many participants breastfeed their babies while taking zuranolone * How many participants do not start new medicine after finishing their zuranolone treatment * How many participants take new medicines after finishing zuranolone * How many participants already tried other medicines for their depression symptoms before joining this study * How many participants take other medicines in general while taking zuranolone This study will be done as follows: People who fill their zuranolone prescription through CVS Specialty Pharmacy will be contact
Primary Outcome
EPDS is a 10-item self-report questionnaire used for the assessment of PPD symptoms. Each item is scored from 0-3, with a total score range of 0-30. Higher scores indicate more severe depressive symptoms.
Conditions Studied
Interventions
- DRUG Zuranolone
Study Locations (1)
Rhode Island
- CVS Health - Woonsocket
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-08-24 |
What NCT07047820 shows while recruiting
NCT07047820 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 150-participant average among 15 other Depression, Postpartum trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Depression, Postpartum appearing as the primary indexed condition, and to 1 intervention - of which Zuranolone is the first listed.
NCT07047820 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT07047820 about?
NCT07047820 is a clinical study titled "A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy". In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD. After giving birth, adults with PPD can suffer from symptoms such as tiredness, sadn...
What is the current status of trial NCT07047820?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-06-30. Estimated completion is 2026-08-24.
What conditions does trial NCT07047820 study?
This clinical trial studies the following conditions: Depression, Postpartum.
What interventions are being tested in trial NCT07047820?
The interventions under investigation include: Zuranolone (DRUG).
Who is sponsoring clinical trial NCT07047820?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07047820 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression, Postpartum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07047820's enrollment target sits among peer trials
200 4th of 15 higher than 12 of 15 other Depression, Postpartum trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression, Postpartum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
IMAGINE: Pilot Trial of a Digital Group Intervention to Prevent Perinatal Depression
RECRUITING · NA
-
HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis
RECRUITING · NA
-
Healing at Home 2.0 - Enhanced Chat Tool for Lowering Postpartum Depression
RECRUITING · NA
-
Enhancing Mental and Physical Health of Women Veterans
ACTIVE NOT RECRUITING · NA
-
CSE v. Epidural for Postpartum Depression
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI